Site icon OncologyTube

ADAURA Trial: Osimertinib for Early Stage EGFR+ NSCLC – 2022 Program: Targeted Therapies Forum

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer.

In this video, Dr. Fred Hirsch discusses the ADAURA Trial, which tested Osimertinib for early stage EGFR+ NSCLC.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Exit mobile version